Ferran Vila-Julià

Ferran Vila-Julià

Auto-generated profile, based on publicly available information

Ferran Vila-Julià

Research Group on Neuromuscular and Mitochondrial Diseases, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, and Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Human Gene Therapy
Verified
Journal Article
Closed access
JTJavier Torres-Torronteras
Javier Torres-Torronteras
Raquel Cabrera-PerezRaquel Cabrera-Perez
Raquel Cabrera-Perez
FVFerran Vila-Julià
Ferran Vila-Julià
Carlo ViscomiCarlo Viscomi
Carlo Viscomi
YCYolanda Camara
Yolanda Camara
RMRamon Marti
Ramon Marti
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is caused by mutations in TYMP, the gene encoding the enzyme thymidine phosphorylase (TP). TP dysfunction results in systemic accumulation of the noxious TP substrates thymidine and deoxyuridine. Gene therapy using either a lentiviral vector or adeno-associated vector (AAV) has proven to be a feasible strategy, as both vectors restore biochemical homeostasis in a murine model of the disease. Here we show that the effect of an AAV containing the TYMP coding sequence transcriptionally targeted to the liver persists at long term in mice. Although the vector copy number was diluted and AAV-mediated liver TP activity eventually reduced or lost after 21 months at the lowest vector doses, the effect was sustained (with a negligible decrease in TP activity) and fully effective on nucleoside homeostasis for at least 21 months at a dose of 2x1012 vg/kg. Macroscopic visual inspection of the animals’ organs at completion of the study showed no adverse effects associated with the treatment. These results further support the feasibility of gene therapy for MNGIE.

1 August 2019 in EBioMedicine
Verified
Journal Article
Open access
CBCora Blázquez-Bermejo
Cora Blázquez-Bermejo
DMDavid Molina-Granada
David Molina-Granada
FVFerran Vila-Julià
Ferran Vila-Julià
DJDaniel Jiménez-Heis
Daniel Jiménez-Heis
XZXiaoshan Zhou
Xiaoshan Zhou
YCYolanda Camara
Yolanda Camara
Thymidine kinase 2 (TK2) catalyses the phosphorylation of deoxythymidine (dThd) and deoxycytidine (dCtd) within mitochondria. TK2 deficiency leads to mtDNA depletion or accumulation of multiple deletions. In patients, TK2 mutations typically manifest as a rapidly progressive myopathy with infantile onset, leading to respiratory insufficiency and encephalopathy in the most severe clinical presentations. TK2-deficient mice develop the most severe form of the disease and die at average postnatal day 16. dThd+dCtd administration delayed disease progression and expanded lifespan of a knockin murine model of the disease. We daily administered TK2 knockout mice (Tk2KO) from postnatal day 4 with equimolar doses of dThd+dCtd, dTMP+dCMP, dThd alone or dCtd alone. We monitored body weight and survival and studied different variables at 12 or 29 days of age. We determined metabolite levels in plasma and target tissues, mtDNA copy number in tissues, and the expression and activities of enzymes with a relevant role in mitochondrial dNTP anabolism or catabolism. dThd+dCtd treatment extended average lifespan of Tk2KO mice from 16 to 34 days, attenuated growth retardation, and rescued mtDNA depletion in skeletal muscle and other target tissues of 12-day-old mice, except in brain. However, the treatment was ineffective in 29-day-old mice that still died prematurely. Bioavailability of dThd and dCtd markedly decreased during mouse development. Activity of enzymes catabolizing dThd and dCtd increased with age in small intestine. Conversely, the activity of the anabolic enzymes decreased in target tissues during mouse development. We also found that administration of dThd alone had the same impact on survival to that of dThd+dCtd, whereas dCtd alone had no influence on lifespan. dThd+dCtd treatment recruits alternative cytosolic salvage pathways for dNTP synthesis, suggesting that this therapy would be of benefit for any Tk2 mutation. dThd accounts for the therapeutic effect of the combined treatment in mice. During the first weeks after birth, mice experience marked tissue-specific metabolic regulations and ontogenetic changes in dNTP metabolism-related enzymes that limit therapeutic efficacy to early developmental stages. FUND: This study was funded by grants from the Spanish Ministry of Industry, Economy and Competitiveness, the Spanish Instituto de Salud Carlos III, the Fundación Inocente, Inocente, AFM Téléthon and the Generalitat de Catalunya. The disclosed funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

1 August 2019 in Human Gene Therapy
Verified
Journal Article
Closed access
Raquel Cabrera-PerezRaquel Cabrera-Perez
Raquel Cabrera-Perez
FVFerran Vila-Julià
Ferran Vila-Julià
MHMichio Hirano
Michio Hirano
FMFederico Mingozzi
Federico Mingozzi
JTJavier Torres-Torronteras
Javier Torres-Torronteras
RMRamon Marti
Ramon Marti
MNGIE (mitochondrial neurogastrointestinal encephalomyopathy) is a devastating disease caused by mutations in TYMP, encoding thymidine phosphorylase (TP). In MNGIE patients, TP dysfunction results in systemic thymidine and deoxyuridine overload, which interferes with mitochondrial DNA replication. Preclinical studies have shown that gene therapy using a lentiviral vector targeted to hematopoietic stem cells or an adeno-associated vector (AAV) transcriptionally targeted to liver are feasible approaches to treat MNGIE. Here, we studied the effect of various promoters (TBG, PGK, HLP, and AAT) and DNA configuration (single-stranded or self-complementary) on expression of the TYMP transgene in the AAV8 serotype in a murine model of MNGIE. All vectors restored liver TP activity and normalized nucleoside homeostasis in mice. However, the liver-specific promoters TBG, HLP, and AAT were more effective than the constitutive PGK promoter, and the self-complementary DNA configuration did not provide any therapeutic advantage over the single-stranded configuration. Among all constructs, only AAV-AAT was effective in all mice treated at the lowest dose (5x1010 vector genomes/kg). As use of the AAT promoter will likely minimize the dose needed to achieve clinical efficacy as compared to the other promoters tested, we propose using the AAT promoter in the vector eventually designed for clinical use.

Verified
Journal Article
Open access
PDF file
JRJavier Ramón
Javier Ramón
FVFerran Vila-Julià
Ferran Vila-Julià
DMDavid Molina-Granada
David Molina-Granada
MMMiguel Molina-Berenguer
Miguel Molina-Berenguer
MMMaria Jesús Melià
Maria Jesús Melià
RMRamon Marti
Ramon Marti
Mitochondrial DNA depletion and multiple deletions syndromes (MDDS) constitute a group of mitochondrial diseases defined by dysfunctional mitochondrial DNA (mtDNA) replication and maintenance. As is the case for many other mitochondrial diseases, the options for the treatment of these disorders are rather limited today. Some aggressive treatments such as liver transplantation or allogeneic stem cell transplantation are among the few available options for patients with some forms of MDDS. However, in recent years, significant advances in our knowledge of the biochemical pathomechanisms accounting for dysfunctional mtDNA replication have been achieved, which has opened new prospects for the treatment of these often fatal diseases. Current strategies under investigation to treat MDDS range from small molecule substrate enhancement approaches to more complex treatments, such as lentiviral or adenoassociated vector-mediated gene therapy. Some of these experimental therapies have already reached the clinical phase with very promising results, however, they are hampered by the fact that these are all rare disorders and so the patient recruitment potential for clinical trials is very limited.

5 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LCLidia Carreño-Gago
Lidia Carreño-Gago
DJDiana Luz Juárez-Flores
Diana Luz Juárez-Flores
JGJosep Grau
Josep Grau
JRJavier Ramón
Javier Ramón
ELEster Lozano
Ester Lozano
EGElena Garcia-Arumí
Elena Garcia-Arumí
Pathogenic variants in the mitochondrial tyrosyl-tRNA synthetase gene (YARS2) were associated with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). However, patients can present mitochondrial myopathy, with exercise intolerance and muscle weakness, leading from mild to lethal phenotypes. Genes implicated in mtDNA replication were studied by Next Generation Sequencing (NGS) and whole exome sequence with the TruSeq Rapid Exome kit (Illumina, San Diego, CA, USA). Mitochondrial protein translation was studied following the Sasarman and Shoubridge protocol and oxygen consumption rates with Agilent Seahorse XF24 Analyzer Mitostress Test, (Agilent, Santa Clara, CA, USA). We report two siblings with two novel compound heterozygous pathogenic variants in YARS2 gene: a single nucleotide deletion in exon 1, c.314delG (p.(Gly105Alafs*4)), which creates a premature stop codon in the amino acid 109, and a single nucleotide change in exon 5 c.1391T>C (p.(Ile464Thr)), that cause a missense variant in amino acid 464. We demonstrate the pathogenicity of these new variants associated with reduced YARS2 mRNA transcript, reduced mitochondrial protein translation and dysfunctional organelle function. These pathogenic variants are responsible for late onset MLASA, herein accompanied by pancreatic insufficiency, observed in both brothers, clinically considered as Pearson’s syndrome. Molecular study of YARS2 gene should be considered in patients presenting Pearson’s syndrome characteristics and MLASA related phenotypes.

6 August 2015 in Expert Opinion on Orphan Drugs
Verified
Journal Article
Closed access
RCRaquel Cabrera-Pérez
Raquel Cabrera-Pérez
JTJavier Torres-Torronteras
Javier Torres-Torronteras
FVFerran Vila-Julià
Ferran Vila-Julià
FOFrancisco J Ortega
Francisco J Ortega
YCYolanda Camara
Yolanda Camara
PDPh D
Ph D